An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

NCT06116968 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Obstructive Hypertrophic Cardiomyopathy

Interventions

DRUG: Aficamten

Sponsor

Corxel Pharmaceuticals